Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Approvals Regulation Japan

Oncology Dominates Japan Approvals, Though Overall Tally Is Lower

  • Analysis

Executive Summary

Although it approved fewer new products last fiscal year, Japan granted access to a number of important new therapies, including in oncology and several for the first time worldwide, helped by continuing reforms at its regulatory body.

Table

View full table

Advertisement

Related Content

Scrip
Japan’s Crossroads: PhRMA’s Scangos Warns Of Policy Change Fallout
Scrip
Japan PMDA To Kick Off New Asia Training Center
Scrip
Japan First To Approve Omarigliptin, Lusutrombopag
Pink Sheet
Speedy review for pioneering drugs: understanding Japan's new Sakigake process

Topics

Related Companies

Advertisement
Tags:
Approvals Regulation Japan
UsernamePublicRestriction

Register

PS118925

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By